Enorama Pharma AB (OSTO:ERMA) Change In Receivables: kr-0.06 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ERMA Enorama Pharma AB OSTO:ERMA
27 GF Score
Price kr0.72
GF Value kr0.27
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Enorama Pharma AB Change In Receivables?

Enorama Pharma AB OSTO:ERMA -15.29% 27 Change In Receivables is kr-0.06 Mil as of Jun. 2026. GuruFocus rates OSTO:ERMA with a GF Score™ of 27/100 and a GF Value™ of kr0.27 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Enorama Pharma AB's change in receivables for the quarter that ended in Jun. 2026 was kr0.07 Mil. It means Enorama Pharma AB's Accounts Receivable declined by kr0.07 Mil from Mar. 2026 to Jun. 2026 .

Enorama Pharma AB's change in receivables for the fiscal year that ended in Dec. 2025 was kr-1.41 Mil. It means Enorama Pharma AB's Accounts Receivable increased by kr1.41 Mil from Dec. 2024 to Dec. 2025 .

Enorama Pharma AB's Accounts Receivable for the quarter that ended in Jun. 2026 was kr1.34 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Enorama Pharma AB's liquidation value for the three months ended in Jun. 2026 was kr-53.44 Mil.

Enorama Pharma AB  (OSTO:ERMA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Enorama Pharma AB's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=1.338/0*91
=

2. In Ben Graham's calculation of liquidation value, Enorama Pharma AB's accounts receivable are only considered to be worth 75% of book value:

Enorama Pharma AB's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=2.098-57.394+0.75 * 1.338+0.5 * 1.7
=-53.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enorama Pharma AB Change In Receivables Related Terms

Enorama Pharma AB Change In Receivables Historical Data

* Premium members only.

The historical data trend for Enorama Pharma AB's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enorama Pharma AB Change In Receivables Chart

Enorama Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.60 4.20 2.26 0.72 -1.41

Enorama Pharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.61 0.58 -0.78 0.07 0.07
OSTO:ERMA
27GF Score
Enorama Pharma AB OSTO:ERMA
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enorama Pharma AB Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of kr-0.06 Mil mean?
Enorama Pharma AB (OSTO:ERMA) has a Change In Receivables of kr-0.06 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Enorama Pharma AB and its competitors.
Is Enorama Pharma AB's Change In Receivables too high?
Enorama Pharma AB's current Change In Receivables is kr-0.06 Mil. Overall, Enorama Pharma AB has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enorama Pharma AB's Change In Receivables compare to ZTS and UTHR?
Enorama Pharma AB's Change In Receivables of kr-0.06 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Enorama Pharma AB and its competitors. Enorama Pharma AB's current Change In Receivables is kr-0.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enorama Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, Enorama Pharma AB (OSTO:ERMA) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.27, compared to a current price of kr0.72 — trading 166.7% above its estimated fair value. The current Change In Receivables is kr-0.06 Mil. Enorama Pharma AB's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Enorama Pharma AB (OSTO:ERMA), the current Change In Receivables is kr-0.06 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enorama Pharma AB (OSTO:ERMA) Overvalued in 2026?

Based on GuruFocus' analysis, Enorama Pharma AB stock appears to be overvalued. The current stock price of kr0.72 is trading 166.7% above its estimated GF Value™ of kr0.27. GuruFocus considers Enorama Pharma AB to be Significantly Overvalued.

Key valuation signals for OSTO:ERMA:

  • Change In Receivables: kr-0.06 Mil
  • GF Value™: kr0.27 vs. price of kr0.72 (166.7% above fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the OSTO:ERMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enorama Pharma AB Business Description

Address Vastra Varvsgatan 19, Malmo, SWE, SE-211 77
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.
27GF Score

Get the complete analysis for OSTO:ERMA

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.72
Price
kr0.27
GF Value